Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.

Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Aug 2005

Su Wen-Pin, Yang Chih-Hsin, Yu Chong-Jen, Shih Jin-Yuan, Hsu Chiun, Yang Pan-Chyr

Abstract excerpt

BACKGROUND AND PURPOSE: Gefitinib is effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, most studies have only investigated patients who have good performance status or are evaluable. This study evaluated the efficacy of geftinib in a consecutive series of patients with NSCLC. METHODS: The treatment response of all gefitinib-treated NSCLC patients from November 2001 to September...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 16193176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.PMID 16193176Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib for advanced non-small cell lung cancer.Semantic proximity Read ↗

[Gefitinib in patients with advanced non-small-cell lung cancer].Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.Semantic proximity Read ↗

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.Semantic proximity Read ↗

Gefitinib. Still no convincing results in non-small cell lung cancer.Semantic proximity Read ↗

Geftinib.Semantic proximity Read ↗

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read ↗

Spotlight on gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.